A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer.
breast cancer; indocyanine green; sentinel lymph node; Oncology; Cancer Research
Abstract :
[en] BACKGROUND: Indocyanine green (ICG) is a promising tracer for sentinel lymph node biopsy in early breast cancer. This randomized study was conducted to evaluate sentinel lymph node biopsy with ICG compared with blue dye as a tracer in woman with early breast cancer without any sign of lymph node invasion.
METHODS: Between January 2019 and November 2020, 240 consecutive women with early breast cancer were enrolled and randomized to sentinel lymph node biopsy using ICG or blue dye. The primary endpoint was the sentinel lymph node detection rate in both arms.
RESULTS: ICG was used in 121 patients and detected sentinel lymph nodes in all patients (detection rate, 100%; 95% CI: 96.9-100.0) while blue dye was used in 119 patients and detected sentinel lymph nodes in 116 patients (detection rate: 97.5%, 95% CI: 92.9-99.1). This analysis indicated the non-inferiority of ICG vs. blue dye tracer (90%CI: -1.9-6.9; p = 0.0009).
CONCLUSION: ICG represents a new promising tracer to detect sentinel lymph nodes in early breast cancer with a detection rate similar to other conventional tracers, and is associated with easy learning and low cost. Our result suggest that this technique is a good alternative to avoid radioactive isotope manipulation.
Disciplines :
Oncology
Author, co-author :
Coibion, Michel ✱; Université de Liège - ULiège ; Gynecology Department, CHC Montlegia, 4020 Liege, Belgium
OLIVIER, Fabrice ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Courtois, Audrey ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique
MAES, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
JERUSALEM, Guy ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
✱ These authors have contributed equally to this work.
Language :
English
Title :
A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer.
Giuliano, A.E.; Kirgan, D.M.; Guenther, J.M.; Morton, D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. In Annals of Surgery; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 1994; pp. 391–401.
Veronesi, U.; Paganelli, G.; Viale, G.; Luini, A.; Zurrida, S.; Galimberti, V.; Intra, M.; Veronesi, P.; Maisonneuve, P.; Gatti, G.; et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study. Lancet Oncol. 2006, 7, 983–990. [CrossRef]
Qiu, S.-Q.; Zhang, G.-J.; Jansen, L.; de Vries, J.; Schröder, C.P.; de Vries, E.G.; van Dam, G.M. Evolution in sentinel lymph node biopsy in breast cancer. Crit. Rev. Oncol. Hematol. 2018, 123, 83–94. [CrossRef] [PubMed]
Krag, D.N.; Anderson, S.; Julian, T.B.; Brown, A.M.; Harlow, S.P.; Ashikaga, T.; Weaver, D.L.; Miller, B.J.; Jalovec, L.M.; Frazier, T.G.; et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007, 8, 881–888. [CrossRef]
Cardoso, F.; Kyriakides, S.; Ohno, S.; Penault-Llorca, F.; Poortmans, P.; Rubio, I.T.; Zackrisson, S.; Senkus, E. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019, 30, 1194–1220. [CrossRef]
Lyman, G.H.; Giuliano, A.E.; Somerfield, M.R.; Benson, A.B.; Bodurka, D.; Burstein, H.J.; Cochran, A.J.; Cody, H.S.; Edge, S.B.; Galper, S.; et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. J. Clin. Oncol. 2005, 23, 7703–7720. [CrossRef] [PubMed]
Ang, C.H.; Tan, M.Y.; Teo, C.; Seah, D.W.; Chen, J.C.; Chan, M.Y.P.; Tan, E.Y. Blue dye is sufficient for sentinel lymph node biopsy in breast cancer. Br. J. Surg. 2014, 101, 383–389. [CrossRef]
Olivier, F.; Courtois, A.; Jossa, V.; Bruck, G.; Aouachria, S.; Coibion, M.; Jerusalem, G. Sentinel lymph node mapping with patent blue dye in patients with breast cancer: A retrospective single institution study. Gland Surgery 2021, 10, 2600. [CrossRef]
Goyal, A. New Technologies for Sentinel Lymph Node Detection. Breast Care 2018, 13, 349–353. [CrossRef] [PubMed]
Xiong, L.; Gazyakan, E.; Yang, W.; Engel, H.; Hünerbein, M.; Kneser, U.; Hirche, C. Indocyanine green fluorescence-guided sentinel node biopsy: A meta-analysis on detection rate and diagnostic performance. Eur. J. Surg. Oncol. 2014, 40, 843–849. [CrossRef] [PubMed]
Verbeek, F.P.R.; Troyan, S.L.; Mieog, J.S.D.; Liefers, G.-J.; Moffitt, L.A.; Rosenberg, M.; Hirshfield-Bartek, J.; Gioux, S.; van de Velde, C.J.H.; Vahrmeijer, A.L.; et al. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: A multicenter experience. Breast Cancer Res. Treat. 2014, 143, 333–342. [CrossRef]
Mok, C.W.; Tan, S.; Zheng, Q.; Shi, L. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open 2019, 3, 445–452. [CrossRef] [PubMed]
Goonawardena, J.; Yong, C.; Law, M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: Systematic review and meta-analysis. Am. J. Surg. 2020, 220, 665–676. [CrossRef] [PubMed]
Kedrzycki, M.S.; Leiloglou, M.; Ashrafian, H.; Jiwa, N.; Thiruchelvam, P.T.R.; Elson, D.S.; Leff, D.R. Meta-analysis Comparing Fluorescence Imaging with Radioisotope and Blue Dye-Guided Sentinel Node Identification for Breast Cancer Surgery. Ann. Surg. Oncol. 2021, 28, 3738–3748. [CrossRef] [PubMed]
Thongvitokomarn, S.; Polchai, N. Indocyanine Green Fluorescence Versus Blue Dye or Radioisotope Regarding Detection Rate of Sentinel Lymph Node Biopsy and Nodes Removed in Breast Cancer: A Systematic Review and Meta-Analysis. Asian Pac. J. Cancer Prev. 2020, 21, 1187–1195. [CrossRef] [PubMed]
Samorani, D.; Fogacci, T.; Panzini, I.; Frisoni, G.; Accardi, F.; Ricci, M.; Fabbri, E.; Nicoletti, S.; Flenghi, L.; Tamburini, E.; et al. The use of indocyanine green to detect sentinel nodes in breast cancer: A prospective study. Eur. J. Surg. Oncol. 2014, 41, 64–70. [CrossRef] [PubMed]
Sugie, T.; Kinoshita, T.; Yamauchi, A.; Bando, H.; Lee, T.; Shinkura, N.; Kato, H.; Ikeda, T.; Ueyama, H.; Masuda, N.; et al. Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. Ann. Surg. Oncol. 2015, 23, 44–50. [CrossRef]
Bonneau, C.; Bendifallah, S.; Reyal, F.; Rossi, L.; Rouzier, R. Association of the number of sentinel lymph nodes harvested with survival in breast cancer. Eur. J. Surg. Oncol. 2014, 41, 52–58. [CrossRef] [PubMed]
Kim, M.K.; Park, H.S.; Kim, J.Y.; Kim, S.; Nam, S.; Park, S.; Kim, S.I. The clinical implication of the number of lymph nodes harvested during sentinel lymph node biopsy and its effects on survival outcome in patients with node-negative breast cancer. Am. J. Surg. 2017, 214, 726–732. [CrossRef]
Gioux, S.; Choi, H.S.; Frangioni, J.V. Image-Guided Surgery Using Invisible Near-Infrared Light: Fundamentals of Clinical Translation. Mol. Imaging 2010, 9, 237–255. [CrossRef] [PubMed]
Cady, B. Consensus on Sentinel Node Biopsy. Breast J. 2002, 8, 123–125. [CrossRef] [PubMed]
Gumus, M.; Gumus, H.; Jones, S.E.; Jones, A.P.; Sever, A.R.; Weeks, J. How Long Will I Be Blue? Prolonged Skin Staining Following Sentinel Lymph Node Biopsy Using Intradermal Patent Blue Dye. Breast Care 2013, 8, 199–202. [CrossRef] [PubMed]
Yin, R.; Ding, L.-Y.; Wei, Q.-Z.; Zhou, Y.; Tang, G.-Y.; Zhu, X. Comparisons of ICG-fluorescence with conventional tracers in sentinel lymph node biopsy for patients with early-stage breast cancer: A meta-analysis. Oncol. Lett. 2020, 21, 114. [CrossRef] [PubMed]
